BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The targeted protein degradation field is expanding\, gone are
  the days of simple proof of concept…. We now have LYTACs\, AUTACs and AT
 TECs as well as numerous PROTAC and Molecular Glue companies with million
 s of dollars worth of investment. C4 netted $182.4 million in IPO\, and N
 urix and Kymera closed funding with $120 million and $102 million apiece.
  With several start-ups launching\, including Lycia and Amphista therapeu
 tics\, investment in this area is booming\, and it’s not slowing down.\n\
 nThere are currently over 85 degraders being considered at various stages
  of development\, both preclinical and clinical\, as well as in discovery
 . However\, key questions are yet to be answered:\n\n\nHow will degrader 
 research translate in the clinic?\nWhy are we still struggling with oral 
 bioavailability?\nHow can we effectively validate novel targets and degra
 de ‘undruggable’ targets of interest?\nWhat can be learned from the new\,
  emerging degrader strategies that are emerging?\n\nOnce again bringing t
 ogether leaders from pharma\, biotech and academia as well as innovative 
 service providers\, the North American Protein Degradation Congress is ba
 ck to give you the full picture from molecular biology right the way up t
 o the latest in medicinal chemistry and clinical data.\n\nLearn to create
  clinically applicable degraders to the entire proteome at the digital No
 rth American Protein Degradation Congress 2021.\n
DTEND:20210224T153100
DTSTAMP:20260512T220338Z
DTSTART:20210216T100000
LOCATION:\,
SEQUENCE:0
SUMMARY:The targeted protein degradation field is expanding\, gone are the
  days of simple proof of concept…. We now have LYTACs\, AUTACs and ATTECs
  as well a...
UID:751e53a8-5317-4cad-b5f2-0eb37d35ca78
END:VEVENT
END:VCALENDAR